Plain-English translation of NCT05895409 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study — meaning researchers watch and collect information rather than test a new medication. The study aims to understand why some people with lung scarring (interstitial lung disease) develop progressive pulmonary fibrosis, and what factors predict who is at highest risk. By following patients over time and collecting blood samples, imaging scans, and lung function tests, researchers hope to identify warning signs that could help doctors provide better care.
Progressive pulmonary fibrosis is a serious condition where lung scarring gets worse over time, but doctors don't fully understand which patients will progress fastest or what risk factors matter most. This study exists to fill that gap by studying patients closely and learning which factors predict disease worsening and patient outcomes.
You likely qualify if…
You likely don't qualify if…
You will visit the study clinic three times over one year: at the start, at 6 months, and at 12 months. At each visit, you'll have blood drawn (about 50 milliliters, or 3.5 tablespoons), undergo a high-resolution CT scan of your lungs, complete full lung function tests, and walk for 6 minutes to measure exercise capacity. The first visit also includes detailed questions about your medical history, smoking, and current medications. There is no new medication to take — this is purely an observation study to track your condition.
AI-generated summary from trial data · Jun 8, 2026 · Not medical advice
China